Alnylam Pharmace. buy Biotechhunter
Summary
This prediction ended on 31.07.20 with a price of €125.52. With a performance of -9.70%, the BUY prediction by Biotechhunter finished with a loss. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | -5.762% | -5.762% | 19.282% | 41.388% |
iShares Core DAX® | -0.116% | 1.953% | 14.155% | 16.268% |
iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% | 43.377% |
iShares Nikkei 225® | -1.721% | 3.263% | 12.922% | 8.501% |
iShares S&P 500 | -1.527% | 0.194% | 27.117% | 41.752% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.